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Abstract: We investigated the HE4 variant-specific expression patterns in various normal 
tissues as well as in normal and malignant endometrial tissues. The relationships between 
mRNA variants and age, body weight, or survival are analyzed. ICAT-labeled normal  
and endometrial cancer (EC) tissues were analyzed with multidimensional liquid 
chromatography followed by tandem mass spectrometry. Levels of HE4 mRNA variants 
were measured by real-time PCR. Mean mRNA levels were compared among 16 normal 
endometrial samples, 14 grade 1 and 14 grade 3 endometrioid EC, 15 papillary serous EC, 
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and 14 normal human tissue samples. The relationship between levels of HE4 variants and 
EC patient characteristics was analyzed with the use of Pearson correlation test. We found 
that, although all five HE4 mRNA variants are detectable in normal tissue samples, their 
expression is highly tissue-specific, with epididymis, trachea, breast and endometrium 
containing the highest levels. HE4-V0, -V1, and -V3 are the most abundant variants in both 
normal and malignant tissues. All variants are significantly increased in both endometrioid 
and papillary serous EC, with higher levels observed in grade 3 endometrioid EC. In the EC 
group, HE4-V1, -V3, and -V4 levels inversely correlate with EC patient survival, whereas 
HE4-V0 levels positively correlate with age. HE4 variants exhibit tissue-specific expression, 
suggesting that each variant may exert distinct functions in normal and malignant cells. HE4 
levels appear to correlate with EC patient survival in a variant-specific manner. When using 
HE4 as a biomarker for EC management, the effects of age should be considered.  
Keywords: HE4; transcription; splice variants; gene expression; endometrial cancer 
 
1. Introduction 
Endometrial cancer (EC) is the most common gynecologic malignancy and the fourth most 
common cancer in females, ranking behind breast, lung and colorectal cancers in the United States. 
While early stage EC has a favorable prognosis, late stage EC is associated with a relatively high rate 
of post-treatment recurrence and mortality. The importance of early diagnosis is underscored by the 
dramatic reduction of five-year survival rates from 96% to 67% and further to 17% for localized, 
regional, and metastatic disease, respectively [1]. Several studies have evaluated the efficacy of 
various tumor markers, including CA125, for EC early detection and management, but only limited 
specificities and sensitivities was observed [2–4].  
HE4 was first cloned as one of four proteins highly expressed in human epididymis [5]. Amino acid 
sequence analysis suggested that HE4 belongs to a whey-acidic-protein (WAP) family and contains 
two four-disulfide core domains (WFDC2). HE4 gene is located on chromosome 20q13.12, a region 
harboring a cluster of genes for WAP domain proteins [6–8]. Although it is well known that at least 
some members of this family serve as endogenous peptide protease inhibitors, the function of HE4 
remains obscure. Using the cDNA microarray technique Schummer et al. found that HE4 is 
overexpressed in ovarian cancer (OC) [9]. Bingle et al. used Northern blot hybridization in order to 
characterize its tissue-specific expression and found that HE4 mRNA is abundant in lung, kidney, and 
the salivary gland [8]. Lu et al. performed oligo-array analysis and observed that HE4 is overexpressed 
in OC in comparison to normal ovarian epithelium [10]. Drs. Drapkin and Galgano et al. analyzed the 
expression of HE4 in a series of normal and malignant tissues and observed high levels of HE4 mRNA 
in the trachea and salivary gland [11,12]. Tissue microarray studies indicate that HE4 protein is present 
in both normal and malignant ovarian and endometrial cells [10–13]. 
Bingle et al. compared the sequences of two lung-derived HE4 ESTs (expressed sequence tags) 
with those of the prototypic HE4 cDNA, leading to the identification of five distinct HE4 mRNA 
variants [8]. Four of these variants (HE4-V0, -V1, -V2, -V4) are generated by differential splicing 
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mechanisms whereas one (HE4-V3) utilizes an alternative promoter as suggested by the presence of an 
extended 5' prime region. The disparate structures and domain arrangements among the HE4 variants 
raised questions on their tissue-specific expression and potentially distinct cellular functions.  
Being a small, secretory glycoprotein [11], HE4 is readily detectable in plasma and the serum levels 
of HE4 are considered a potential biomarker for ovarian cancer diagnosis and management [13–16]. 
An antibody-based ELISA has been developed to measure HE4 serum levels in various clinical 
settings [17–19]. It has been reported that HE4 alone or in combination with CA125 has higher 
sensitivity than any other single marker or combination of markers, in early detection [20–22], 
diagnosis [15,23–26], risk stratification [27] and prediction of postsurgical outcome [10,20,24,28] for 
patients with OC. With regards to EC, Moore et al. found that HE4 serum levels are consistently 
elevated in all stages of EC and that it is more sensitive in detecting early-stage disease than  
CA125 [29]. Bignotti et al. assessed the diagnostic and prognostic value of HE4 in EC. In their study, 
a significant correlation was found between increased HE4 serum levels and aggressive EC  
phenotype [30]. Based on these findings, HE4 test has been proposed as a valuable tool for the triage 
of patients presenting with a pelvic mass [31–33]. It is noteworthy that, despite the data in favor of 
HE4 protein levels as a useful biomarker, negative results from several studies challenged  
the predictive value of the ROMA algorithm when HE4 was used alone or in combination with  
CA125 [34,35].  
While most studies suggest that HE4 is a clinically useful biomarker in EC and OC, the assays used 
to measure mRNA or protein levels were designed based on the structure of the prototype HE4, 
designated as HE4-V0 in this report. In previous studies, no distinction was made among the multiple 
structurally and potentially functionally diverged HE4 variants. The goal of this study is to compare 
HE4 mRNA variants-specific expression in normal and malignant endometrial tissues, and to analyze 
the relationship between HE4 variant-specific mRNA levels and clinical features including age, 
surgical stage and survival.  
2. Results 
2.1. HE4 Protein Is Overexpressed in Endometrial Cancer  
Six pairs of matched normal and endometrial cancer tissue samples were prepared and analyzed on 
mass spectrometry. Figure S1 shows representative chromatograms for LC and mass spectrometry 
identification and comparison of HE4 levels between EC and normal endometrium samples. 
Thousands of proteins were identified from each of these pairs (3006, 2826, 2434, 2389, 1925, and 
1803 for pairs 1 to 6, respectively; 75% confidence level). A more in-depth analysis of the data 
resulted in the identification of a group of 77 proteins which presented a greater than 1.5-fold changes 
in their expression levels between normal and cancer tissue in at least two out of six pairs of  
samples [36]. These proteins were found to be involved in a broad spectrum of cell functions including 
cellular structure determination, cell signaling, transcription control, as well as cell cycle and apoptosis 
regulation (Figure S1). Table 1 presents data on 8 representative proteins out of the 77 that exhibiting 
altered expression in endometrioid cancers. In accordance with previous studies [24,30], HE4 was 
found to be one of the 27 proteins significantly up-regulated in EC (Figure S2).  
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Table 1. Representative proteins identified by Isotope-Coded Affinity Tag (ICAT)-mass spectrometry. The table provides basic information 
on accession number (GI number is NCBI/PubMed protein ID number), protein identity, cellular function, numbers of paired-samples in 
which the protein was detected (Presence), the average ratio between endometrioid cancers and normal controls (Mean), and the standard 
errors (STE).  
Accession ID number Protein identity Function Presence Peptide Mean STE 
GI: 32307109 HE4, WAP four-disulfide core domain 
protein 3 precursor, WFDC2 
Male fertility function. Putative ovarian 
tumor marker 
2 1 2.45 1.23 
GI: 3859849 LIM protein SLIMMER Intracellular signaling pathway 3 1 2.39 1.11 
GI: 15779184 FLNA protein, Filamin Actin binding, cell structure and 
mobility 
4 1 2.00 0.57 
GI: 4504165 Gelsolin Calcium-regulated, actin modulation; 
Silenced in tumor cells 
2 2 0.52 0.07 
GI: 86947 Galectin 1, beta-galactoside-binding 
lectin, placental 
Cell differentiation and apoptosis 5 2 0.25 0.05 
GI: 3193336 DBI-related protein Fatty acid metabolism 2 1 0.54 0.20 
GI: 37544577 Hypothetical protein XP_294867 Unknown 5 4 1.60 0.13 
GI: 27545315 Translational activator of cytochrome c 
oxidase 1 
Translational activator 5 10 1.58 0.21 
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2.2. Design of HE4 Variant-Specific PCR Primers  
We took advantage of the distinct intra-exon sequences and exon-exon boundaries within the HE4 
variants to design variant-specific PCR primers (Figure 1). The designations and sequences of these 
PCR primers are listed in Table 2. PCR conditions were extensively optimized to ensure specific and 
linear amplification. Aliquots of the real-time PCR products were resolved electrophoretically in 
agarose gels and subsequently visualized with ethidium bromide staining. A single band pattern with a 
predicted size indicated that specific amplification had been achieved (Figure 2).  
Figure 1. Schematic outline of real-time PCR primer design for each HE4 variant. The 
structures of HE4 variants were illustrated with the six exons marked in different colors. 
The locations of real-time PCR primers were indicated by arrows. On the bottom the HE4 
genomic structure of HE4 prototype (HE4-V0) (NM_006103.3, GeneID: 10406) was 
shown based on the information from NCBI website [37]. The HE4 gene is located at 
20q13.12, spanning 1429614nt to 14308137nt in NM_006103.3.  
 
Table 2. Real-time PCR primers for HE4 transcript variants. The sequences and designation 
of PCR primers for real-time PCR measurement of HE4 transcript variant were listed. 
Primer name Primer sequence 
WFDC2 = HE4-V0 Forward 5'-CCG ACA ACC TCA AGT GCT G-3' 
WFDC2 = HE4-V0 Reverse 5'-CGA GCT GGG GAA AGT TAA TG-3' 
HE4-V1 Forward 5'-AAT GGC CAA CTG GCT GAG-3' 
HE4-V1 Reverse 5'-TTT GAG AGA GTC CCC AGC TC-3' 
HE4-V2 Forward 5'-CCA TGC CTG CTT GTC GCC-3' 
HE4-V2 Reverse 5'-CAG GAA CCC TCC TTA TCT GA-3' 
HE4-V3 Forward 5'-GCC ATG CTG CAG GTA CAA GT-3' 
HE4-V3 Reverse 5'-ATC TGG GTA GAA AAA GGA GTA AGG-3' 
HE4-V4 Forward 5'-CCC AAT GCA CTG TTC CAC T-3' 
HE4-V4 Reverse 5'-AGT CCC AAG TGG GCC TTC-3' 
36B4 Forward 5'-ATG CAG CAG ATC CGC ATG-3' 
36B4 Reverse 5'-TCA TGG TGT TCT TGC CCA TCA-3' 
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Figure 2. Gel electrophoresis of real-time PCR products. Real-time PCR products of the 
five HE4 transcript variants are obtained from normal endometrial specimen, and separated 
in 2% agarose gel. The real-time PCR product size for each variant was: for HE4-V0,  
112 bp; HE4-V1,131 bp; HE4-V2 96 bp; HE4-V3, 74 bp; HE4-V4, 84 bp. 36B4 (63 bp) 
was used as an internal control. The single band pattern indicates specific amplification of 
cDNA by real-time PCR.  
 
2.3. Expression of HE4 mRNA Variants in Normal Tissues  
To obtain general knowledge on the HE4 mRNA variants distribution, we first compared by  
real-time PCR the levels of their expression in 14 normal human tissues, including epididymis,  
skeletal muscle (s. muscle), testis, prostate, lung, placenta, trachea, kidney, peripheral blood  
lymphocyte (PBL), colon, liver, breast, ovary and endometrium. Relative mRNA levels of HE4 
variants are shown in Figure 3, which indicates a high degree of variability across different tissues. 
Overall, epididymis and trachea express the highest levels of HE4 mRNA variants followed by breast, 
endometrium, lung and prostate, which expressed intermediate levels. Interestingly, this is consistent 
with Dr. Drapkin et al.’s previous finding [11]. The remaining tissues tested express only low to 
moderate levels of HE4 mRNA variants. Different tissues express diverged levels of HE4 variants. For 
example, the highest levels of HE4-V0 and -V2 were found in the epididymis, whereas the highest 
levels of HE4-V1, -V3 and -V4 were in the trachea. HE4-V3 is also expressed at a relatively high level 
in breast tissue.  
In order to compare horizontally the levels of each variant across various tissues, the data was 
rearranged and presented by tissues. Figure 4 shows that the HE4-V0 to -V4 distribution in  
normal endometrium, breast, epididymis, and trachea. The distribution in the rest 10 types of tissues 
was shown in the supplemental data Figure S3. HE4-V0 represents the most abundant variant,  
followed by HE4-V1 and -V3 at approximately 10- to 100-fold lower levels than HE4-V0. Diminished 
levels of HE4-V2 and -V4, at approximately 100- to 1000-fold lower than HE4-V0, were detected in 
all the tissues.  
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Figure 3. HE4 variant expression levels in normal tissues. Total RNA was extracted from 
14 types of normal human tissues: epididymis, skeletal muscle (S. Muscle), testis, prostate, 
lung, placenta, trachea, kidney, peripheral blood lymphocyte (PBL), colon, liver, breast, 
ovary and endometrium. Reverse transcription and real-time PCR were performed on these 
samples. The expression levels of each variant in different tissues were normalized by the 
level of epididymis (set as 100). The mRNA levels of HE4 were ranked in three groups: 
<5% was ranked as low, 5%–50% was ranked as moderate, >50% was ranked as high. In 
general, all the variants were expressed at the highest levels in epididymis or trachea, 
moderate levels in prostate, lung, breast and endometrium, and very low levels in skeletal 
muscle, testis, placenta, kidney, PBL, colon and liver.  
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Figure 4. Comparison of HE4 variant expression levels in normal tissues. The data from 
Figure 3 was re-set to best describe the HE4 variant expression levels in epididymis, 
breast, trachea and endometrium. The relative expression levels were converted based on 
HE4-V0 (set as 100). Average and standard errors were indicated by the number on the  
top of bars. 
 
To further analyze the tissue/organ-specific expression patterns of the 5 HE4 variants, we 
performed regression analysis in the 13 normal tissues/organs. Similar expression patterns of HE4 
variants were found among the majority of the tissue types, with correlation coefficients all exceeding 
0.88 and p values small than 0.05 (Table 3). Thus, the results indicated a significant inter-correlation 
among the different HE4 variants (N = 5) in those normal tissues. Interestingly, no significant 
correlation in the HE4 variant expression patterns could be established between the colon and several 
tissues such as ovary, PBL, placenta, kidney and prostate. Consequently, the colon appears to represent 
a special tissue with a unique HE4 variant expression pattern when compared to other human tissues. It 
is intriguing to observe this highly consistent HE4 variant expression patterns among a variety of 
human tissues, and at the same time, a dramatic divergence between colon and other tissues. The 
regulatory mechanism and functional significance of this phenomenon is not clear at this time.  
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Table 3. Correlation analysis of HE4 splicing variants among normal tissues. There was a significant correlation between the HE4 variant 
expression patterns among the all the normal tissues except for Colon (r > 0.88, p < 0.05). The expression pattern in Colon was not associated 
with those of Ovary, Placenta, PBL, Prostate and Kidney (marked as *). 
 Colon Endometrial Epidydimus Kidney Liver Lung S. muscle Ovary PBL Placental Prostate Testis Trachea 
colon 1 0.936 0.963 0.877 0.892 0.887 0.886 0.871 0.858 0.812 0.869 0.945 0.913 
prob > |r|  0.019 0.009 0.051 * 0.042 0.045 0.046 0.055 * 0.063 * 0.095 * 0.056 * 0.015 0.031 
endometrial  1 0.993 0.987 0.991 0.991 0.975 0.986 0.980 0.944 0.985 0.994 0.991 
prob > |r|   0.001 0.002 0.001 0.001 0.005 0.002 0.004 0.016 0.002 0.001 0.001 
epidydimus   1 0.963 0.976 0.969 0.958 0.961 0.950 0.929 0.965 0.985 0.986 
prob > |r|    0.008 0.004 0.007 0.010 0.009 0.014 0.022 0.008 0.002 0.002 
kidney    1 0.995 1.000 0.963 1.000 0.995 0.962 0.997 0.985 0.984 
prob > |r|     0.000 <0.0001 0.009 <0.0001 0.000 0.009 0.000 0.002 0.002 
liver     1 0.995 0.955 0.994 0.984 0.977 0.999 0.984 0.996 
prob > |r|      0.000 0.011 0.001 0.003 0.004 <0.0001 0.003 0.000 
lung      1 0.970 0.999 0.996 0.957 0.996 0.987 0.985 
prob > |r|       0.006 <0.0001 0.000 0.011 0.000 0.002 0.002 
s. muscle       1 0.967 0.977 0.885 0.953 0.959 0.947 
prob > |r|        0.007 0.004 0.046 0.012 0.010 0.015 
ovary        1 0.997 0.960 0.996 0.981 0.982 
prob > |r|         0.000 0.010 0.000 0.003 0.003 
PBL         1 0.938 0.987 0.975 0.967 
prob > |r|          0.019 0.002 0.005 0.007 
placental          1 0.980 0.928 0.977 
prob > |r|           0.004 0.023 0.004 
prostate           1 0.977 0.991 
prob > |r|            0.004 0.001 
testis            1 0.981 
prob > |r|             0.003 
trachea             1 
prob > |r|              
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2.4. Increased Levels of HE4 mRNA Variants in Endometrial Cancer  
Using the same set of primers we performed real-time PCR to compare the HE4 variant-specific 
expression between EC and normal endometrium tissues (Figure 5). The mRNA levels of HE4-V0,  
-V1, and -V4 were significantly higher in grade 1 and grade 3 endometrioid EC than in normal 
endometrium (p < 0.05). mRNA of HE4-V2 and -V3 were increased in grade 1 compared to normal 
endometrium (p < 0.05). The difference in the expression levels of HE4-V2 and -V3 in grade 3 EC 
compared to normal endometrium were of borderline significance (p = 0.057, p = 0.067, respectively). 
Likewise, the levels of all variants but HE4-V0 (p = 0.17) were significantly increased in papillary 
serous EC compared to normal endometrium (p < 0.05). The individual expression levels of each HE4 
variant compared to housekeeping gene measured in each clinical case were shown in the Figure S4 
(supplemental data section). As it was observed in all normal tissues, HE4-V0 is the most abundant 
variant among the five counterparts in malignant as well as benign endometrial tissues. 
Figure 5. Increased HE4 variant expression levels in EC. mRNA levels of the five  
HE4 variants were measured in normal endometrium, grade 1 and 3 endometrioid cancer, 
and serous cancers by real-time PCR. HE4 mRNA levels in normal endometrium were set 
as 1. Statistical significance (p < 0.05) was indicated by asterisks.  
 
While HE4 expression patterns in grade 1 endometrioid, grade 3 endometrioid and papillary serous 
EC were significantly inter-correlated with each other (p < 0.05) (Table S1), they were not statistically 
correlated with the expression patterns in normal endometrium (p = 0.32, p = 0.18, p = 0.23 
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respectively), drawing a clear line that separate the malignant and normal endometrial tissues as two 
distinct entities.  
2.5. Increased HE4 Expression Levels Are Negatively Associated with Patient Outcome  
The relationship between HE4 variant expression levels and clinical outcomes were analyzed. 
Clinical data on survival, BMI and age are retrieved and summarized in supplemental Table S2. No 
statistically significant correlation was observed between HE4 variants levels and age or BMI in the 
normal control group (Table 4). In contrast, a significant inverse correlation was found between  
HE4-V1, -V3, -V4 mRNA levels and EC patient survival time in grade 1 and grade 3 endometrioid 
cancer sub-cohort (Table 5) (p = 0.031, p = 0.048, p = 0.01, respectively). The detailed one-to-one 
correlation is documented in Figure 6. Interestingly, in the same endometrioid cancer sub-cohort,  
HE4-V0 levels were found to be positively correlated with patients’ age (p = 0.033), but not with body 
mass index (BMI) (p = 0.79) or survival (p = 0.23) (Table 5). Multivariate analysis adjusted by patient 
age and survival time confirmed that age was independently correlated with HE4 levels. It is surprising 
to see a lack of significant correlation between mRNA levels of the five variants of HE4 and patient 
survival, BMI or age in the serous cancer group (Table 6). The mean levels of Age, BMI, and number 
of study subjects are presented in Table 7. The different relationships between HE4 variant expression 
levels and clinical parameters in the endometrioid and serous tumors underscore a divergence between 
the type I and II EC cases, as expected by their differing etiology and molecular make-up. 
Table 4. Correlation of HE4 variants expression levels with endometrial cancer (EC) 
patients’ clinical data. The Pearson correlation coefficient analysis is performed between 
HE4 variant levels and patients’ age, BMI, and survival time. No significant correlation 
between HE4 variant levels and clinical data was found in normal endometrium group 
(Table 4).  
 BMI Age 
Log10(V0) −0.172 −0.184 
 p = 0.524 0.495 
 n = 16 16 
Log10(V1) 0.086 −0.076 
 p = 0.752 0.779 
 n = 16 16 
Log10(V2) 0.046 −0.075 
 p = 0.865 0.782 
 n = 16 16 
Log10(V3) −0.087 0.377 
 p = 0.749 0.150 
 n = 16 16 
Log10(V4) 0.229 0.134 
 p = 0.394 0.620 
 n = 16 16 
Prob > |r| under H0:Rho = 0. 
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Table 5. Correlation of HE4 variants expression levels with endometriod EC patients’ 
clinical data. A significant inverse correlation between three of the variants (HE4-V1, -V3, 
-V4) and patients’ survival were found in endometrioid EC group. There was also a 
positive correlation found between variants HE4-V0 and patients’ age. No significant 
correlation was found between HE4 expression levels and patients’ BMI in this group.  
 Survival BMI Age 
Log10(V0) −0.285 −0.057 0.419 
 p = 0.236  0.791 0.033 
 n = 19 24 26 
Log10(V1) −0.497 −0.114 0.226 
 p = 0.031 0.595 0.267 
 n = 19 24 26 
Log10(V2) −0.338 −0.085 0.179 
 p = 0.157 0.692 0.380 
 n = 19 24 26 
Log10(V3) −0.459 −0.038 0.262 
 p = 0.048 0.858 0.196 
 n = 19 24 26 
Log10(V4) −0.572 −0.056 0.299 
 p = 0.011 0.796 0.138 
 n = 19 24 26 
Prob > |r| under H0:Rho = 0. 
Figure 6. Correlation between HE4 variants mRNA levels and EC patient survival time. A 
significant inverse correlation was found between HE4-V1, -V3, -V4 mRNA levels and EC 
patient survival time in this endometrioid cancer sub-cohort (p = 0.031, p = 0.048,  
p = 0.01, respectively, n = 19). 
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Table 6. Correlation of HE4 variants expression levels with Serous EC patients’ clinical 
data. In serous cancer group, there was no significant correlation between the variants 
expression and patients’ survival, BMI and Age. 
 Survival BMI Age 
Log10(V0) 0.088 0.253 −0.075 
 p = 0.774 0.364 0.790 
 n = 13 15 15 
Log10(V1) 0.304 0.145 −0.077 
 p = 0.313 0.605 0.786 
 n = 13 15 15 
Log10(V2) 0.247 0.454 −0.254 
 p = 0.416 0.089 0.361 
 n = 13 15 15 
Log10(V3) 0.32 0.112 −0.085 
 p = 0.287 0.691 0.763 
 n = 13 15 15 
Log10(V4) 0.332 0.482 −0.074 
 p = 0.268 0.069 0.794 
 n = 13 15 15 
Prob > |r| under H0:Rho = 0. 
Table 7. In endometrioid cancer group, the cases numbers (N), mean value (mean), the 
maximum value and minimum value on patients’ survival, BMI and age are summarized. 
 N Mean σ Minimum Maximum 
Survival 19 68.7 43.1 1 180 
BMI 24 34.4 9.4 19.6 63.5 
Age 26 59.7 12.8 39 91 
3. Discussion  
Utilization of alternative splicing or alternative promoters allows a single gene to encode multiple 
structurally and functionally related proteins. These processes have greatly increased the diversity of 
proteome, and may constitute an effective and economical mechanism for fine-tuned regulations of 
cell functions. Indeed, complex posttranscriptional regulatory mechanisms appear to be a common 
feature of the WAP domain genes. Elafin and SLPI genes, the two best-studied WAP domain family 
members, are both able to generate multiple splicing products [38–41]. Eppin, another recently 
identified WAP protein, is encoded by a single-copy gene as evidenced by the presence of single band 
on the Southern blotting of human genomic DNA [42]. Computer-aided analysis of Eppin sequence 
predicts the existence of three splice variants, all of which conform to the AG/GT splicing rule [42].  
HE4 gene generates five mRNA variants as a result of alternative splicing and utilization of 
alternative promoters [8]. Amino acid sequence and domain analysis of the deduced peptides predicts 
that the HE4 N-terminal and C-terminal WAP domains are encoded by exon 2 and exon 5, 
respectively. Based on the arrangement of WAP domains, the five HE4 transcript variants can be 
categorized into three groups: Group 1 (HE4-V0 and -V1) contains both the N-terminal and C-terminal 
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WAP domains; Group 2 (HE4-V4) contains only the N-terminal WAP domain; Group 3 (HE4-V2  
and -V3) contains only the C-terminal WAP domain. In addition, HE4-V0, -V1, and -V4 share the 
same secretory signal peptide and are therefore likely to be present in the plasma. For the rest of HE4 
variants, HE4-V2 signal peptide is homologous to that of HE4-V0 with the exception of a deletion in 
the last 10 amino acids, suggesting differential regulation of secretion; HE4-V3 does not contain a 
consensus signal sequence, raising questions regarding its cellular location and secretory potential [8]. 
In this study, we provide experimental data showing that these structurally unique HE4 variants are 
concurrently expressed in various human tissues. Although all variants were readily detectable by  
real-time PCR, their expression levels differ dramatically, by as many as 10,000 fold. Taken together, 
these data suggest that the production of HE4 variants, either through differential splicing or use of 
alternative promoters, are subject to tight and distinct regulation. Furthermore, the structural 
divergence, differential locations, e.g., secreted form verses intracellular form, and markedly different 
expression patterns suggest that they may be implicated in tissue-specific functions.  
Although total HE4 expressions have been characterized in a variety of normal and cancerous 
tissues by many laboratories [8,11,12], HE4 variant-specific expression patterns has not been 
comprehensively investigated. We showed that the expression patterns of the five HE4 variants share 
certain similarity among normal tissues. On the contrary, HE4 variant expression patterns diverge 
significantly between malignant and normal endometrial tissues. This observation in conjunction with 
the fact that these variants are significantly overexpressed in endometrial cancer cells points to a 
potential role(s) for HE4 in EC tumorigenesis or progression. In a parallel study, we have tested this 
hypothesis. We demonstrated that at least the prototype HE4-V0 exhibits a potent tumor-promoting 
activity both in vitro and in vivo [43]. Given the fact that the deduced peptides from these mRNA 
variants contain a different number of WAP domains, and that the N- and C-terminal WAP domains share 
low homology, it is unlikely that these peptides carry out the same functions. Comparative variant-specific 
functional studies are required to delineate the roles of each variant in EC development.  
In addition to its potential pathological role(s), HE4 levels may also reflect the status of EC 
progression from a clinical point of view. Yamashita et al. performed immunohistochemistry on lung 
adenocarcinoma tissue samples to investigate the predictive value of HE4 for patient outcome and 
found that the five-year disease-free survival in the HE4-positive group (44.6%) was significantly 
lower than that in the HE4-negative group (82.3%, p = 0.001). Moreover, HE4 expression and the 
nodal status were noted to be independent prognostic factors for disease-free and overall survival [44]. 
Kamei et al. examined the HE4 expression in breast cancer tissues and confirmed that HE4 protein level 
was associated with lymph node invasion. Furthermore, the five-year survival in the HE4-positive  
group (58.6%) was significantly worse than that in the HE4-negative group (85.6%, p = 0.04) [45]. 
Bignotti, et al. found that high serum HE4 levels correlated with reduced survival in the poorly 
differentiated EC cohort [30]. A study from our group recently indicated a correlation between the 
high serum HE4 levels and high surgical stage, increased myometrial invasion, and large primary 
tumor diameters in EC patients [46]. In the current study although all five HE4 mRNA variants were 
significantly increased in malignant compared to normal endometrium, only the levels of three variants 
(HE4-V1, -V3, and -V4) were found to be correlated with the patient survival data. This finding 
suggests that not all HE4 variants are predictive of patient outcomes, which underscores the 
importance of a variant-specific approach in the measurement of HE4 levels. It is noteworthy that the 
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variants associated with survival (HE4-V1, -V3, and -V4) are those expressed at the highest level in 
the trachea but not the ones (HE4-V0 and -V2) expressed at the highest levels in the epididymis. 
Neither the interpretation nor the significance of this observation is clear at this time.  
Despite the ambiguity regarding each variant’s distinct function, correlation between the expression 
of certain HE4 variants and patient survival may prove important from a clinical perspective. 
Numerous studies have shown that mRNA detection in serum as well as in other body fluids may 
provide a promising approach to cancer assessment and management. Tumor cell mRNA in plasma 
may originate from necrosis or apoptosis of circulating cancer cells, or as the result of an active release 
mechanism in which mRNA transportation occurs through vesicle-like structures [47,48]. Based on the 
high expression levels of the HE4 mRNA variants in EC tissue samples, the same mRNA variants may 
be detectable in patients’ serum as well. Thus, the variant-specific approach may offer insights into EC 
detection, prognostication, and disease monitoring. The optimal technical parameters we outline here 
could serve as a foundation for future studies along this direction.  
Because both ovary and endometrium develop from the Müllerian system [49–51], carcinomas 
arising from these sites tend to have similar etiological factors, gene expression profiles, and 
tumorigenic mechanisms. Consequently, defining the expression patterns of HE4 variants in normal 
and malignant ovarian tissues may demonstrate similar findings. However, early detection of HE4 
variants is more convenient in EC compared to ovarian or other types of cancer given that tumor cells 
can be collected non-invasively in menses or vaginal secretions by the use of pap smear-like devices or 
tampons [52]. RNA samples extracted from pap smear specimens have been successfully utilized for 
transcriptome profiling in the past [53]. The currently available HE4 ELISA assay measures the total 
HE4 levels and does not distinguish the HE4 protein species produced by different HE4 mRNA 
variants. One could envision using either antibody-based ELISA or mRNA-based PCR assays to detect 
HE4 mRNA variants in these body fluids for the purpose of early EC detection.  
Anastasi et al. observed that serum HE4 levels vary substantially among the follicular, ovulatory 
and luteal phases in healthy young women, suggesting hormonal regulation of HE4 production in the 
ovary and other somatic tissues [28]; recently, Levanon et al. have also shown that normal fallopian 
tube secretes HE4, these data indicate the characteristic of the HE4 origin from the Mullerian 
epithelium [54]. Malignant endometrial cells express varied levels of steroid hormone receptors due to 
differential epigenetic modification. This may have a significant effect on HE4 variant expression 
patterns and at the same time, cancers’ response to hormonal therapy. Since most of the patients 
included in our study were postmenopausal women, we could not assess the influence of menstrual 
cycle on HE4 expression. Interestingly, HE4-V0, the most abundant HE4 variant, was found to be 
correlated with age in the endometrioid cancer cohort. This result is consistent with another study 
showing that serum HE4 levels are closely correlated with age in EC patients [46]. Given the fact that 
the relationship between HE4 mRNA levels and age is not evident in the normal control group, this 
age-related change of HE4 levels may reflect tumor characteristics rather than varying hormonal 
status. This hypothesis is further supported by the data from our recent study in which HE4 serum 
levels positively correlated with high-risk tumor characteristics in EC [46]. The association between 
HE4 /HE4 levels and age also suggest that the age-adjusted HE4 levels may be more accurate criteria 
for cancer diagnosis and prognostication. We should point out that this observation is in agreement 
with the data recently published by Bolstad et al. [55]. In that study, it was found that higher HE4 
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levels are associated with age and smoking status, as well as creatinine levels and BMI in healthy 
subjects, while the two later factors are also associated with age. These new findings are very 
important in the way that when HE4 variants are applied as a biomarker for EC diagnosis, these factors 
need to be taken into account to rule out the possibility that the elevated HE4 levels may be caused by 
the patients’ age, smoking status and BMI in addition to the tumor itself. As the higher creatinine 
levels and smoking status are associated with age, the relationship between HE4 levels and creatinine 
levels would be an interesting issue for future studies. 
This study is to our knowledge the first one to demonstrate a tissue-specific distribution of HE4 
variants and establish an HE4 variant-specific correlation with survival in EC. Furthermore, we 
suggest that a variant-specific approach may prove useful for improving the current use of HE4 assays 
in the diagnosis, triage and postsurgical surveillance for the patient with EC.  
4. Experimental Section 
4.1. Collection of Tissue Samples  
Both normal and malignant endometrial tissue samples were collected randomly from patients 
treated at Mayo Clinic for a variety of gynecologic conditions. Central pathology review was 
conducted to verify institutional diagnoses and eliminate variability among experts. Samples obtained 
from patients undergoing hysterectomy for benign indications were used as normal endometrium 
controls. Endometrial tissue specimens were obtained from 14 patients with grade 1 EC, 14 patients 
with grade 3 endometrioid EC, and 15 patients with papillary serous EC, and 16 patients with normal 
endometrium. For the six pairs of tissues analyzed by mass spectrometry study, EC and normal 
samples were selected based on match criteria of age (±5 years), body weight (±10 kg) and 
menopausal status, which is a separate pool of the above described cohort. Clinical data on survival, 
BMI and age were retrieved and confirmed for most of the patients. All samples were snap frozen, 
stored at −80 °C. For total RNA extraction, tissues were cut into 10 μm-thick series sections; one 
section was used for H&E staining to define the tumor tissues (circled with marker) vs. myometrium. 
10 series sections were matched with H&E stained one, only tumor tissues were macro-dissected to 
ensure that at least 50% of the samples were tumor tissue. These studies were approved by the 
Institutional Review Board of Mayo Foundation (IRB# 07-004290). In accordance with the Helsinki 
Declaration and Minnesota Statute for Use of Medical Information in Research, only patients who 
consented to the use of their medical records were included in the study.  
4.2. Tissue Preparation and ICAT Labeling Procedure 
Specimens were mixed with 0.5 ml of lysis buffer (0.5 mM pH 8.3 Tris plus 0.1% SDS), and a glass 
grinder was used to homogenize the tissues. After separating the supernatant from the tissue debris by 
centrifugation at 13523 RCF (or 12,000 rpm), the supernatant was used for Isotope-Coded Affinity 
Tag (ICAT) labeling for a high throughput comparison of normal and malignant endometrial tissues. 
Protein concentrations were measured using the Bio-Rad Protein Assay Kit (Bio-Rad, Hercule, CA, 
USA). 100 μg of protein was labeled with Cleavable ICAT (cICAT) purchased from Applied 
Biosystems (Applied Biosystems, Foster City, CA, USA). We labeled the control samples with light 
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isotopes (containing 8 hydrogens, D0) and the EC samples with heavy isotopes (containing  
8 deuteriums, D8). Briefly, protein extracts were mixed with 2 μL of reducing agent. After boiling for 
10 min, the labeling reaction was carried out overnight at 37 °C. Each labeled EC sample was 
combined with its labeled control sample and the mixture was incubated overnight at 37 °C in 
digestion buffer solution containing 2 μL of CaCl2 and 1 vial of trypsin as provided in the kit. 
Following digestion, the peptide mixture was subject to cation ion exchange purification and affinity 
purification using an Avidin column to collect peptides containing ICAT-labeled cysteine. 100 μL of 
cleavage reagent was added and the mixture was kept at 37 °C for 2 h to cleave the biotin portion. 
Cleavage mixture was dried under vacuum and stored at −80 °C until mass spectrometric analysis.  
4.3. Multidimensional Liquid Chromatography Coupled to Tandem Mass Spectrometry (LC/MS/MS) 
The cleaved samples were separated into 8 fractions on a cation exchange column (Biox SCX  
300 mm × 5 cm, Dionex, Sunnyvale, CA, USA) using an off-line Agilent 1100 series capillary liquid 
chromatography system (Wilmington, DE, USA). The API QSTAR Pulsar I, a hybrid quadrupole  
time-of-flight mass spectrometer (Applied Biosystems, Foster City, CA, USA) was used to perform the 
LC/MS/MS analysis of the peptides from each fraction with the help of the Analyst QS 1.0 software 
(Applied Biosystems, Foster City, CA, USA). The QSTAR was configured with the Protana Nanospray 
Source (Proxeon, Denmark), and coupled to an Ultimate Nano liquid chromatography system (Dionex, 
Sunnyvale, CA, USA) equipped with a Zorbax C18 100 mm × 150 mm microbore column (Agilents, 
Wilmington, DE, USA). Mass spectrometry analysis consists of a one-second survey scan from 400 to 
1600 mass-to-charge ratio (m/z) followed by two-second MS/MS fragmentation ion scan with a 
threshold of 10 counts per second. Once the three most intense ions were fragmented in each survey scan, 
they were excluded from repeated fragmentation for 60 s. The collision energy applied varied automatically 
depending on the precursor m/z and charge state. The peptide mass tolerance was set at 0.2 Da. 
4.4. Data Analysis of LC/ICAT 
Acquired data were searched against the CDS FASTA database and quantified using ProICAT  
1.0 SP3 software (Applied Biosystems, Foster City, CA, USA). Relative quantification of proteins  
was performed on the TOF (time of flight) MS scan by calculating the ratio between the areas 
representing the light- and heavy-labeled peptide peaks. Two different search engines were used for 
protein identification, the ProICAT and the Mascot (Matrix Science, Boston, MA, USA) from the 
human non-redundant database. Only the proteins with a confidence level of 90% were used for further 
identification and quantification. The protein function annotation was supplemented using an online 
bioinformatics program, the Bioinformatics Harvester [56]. All proteins identified (Table 1) were 
individually verified by manually inspecting its precursor on chromatogram and mass spectrum. The 
protein accession numbers (GI number) are from NCBI protein database. 
4.5. RNA Isolation, cDNA Synthesis, and Quantitative PCR 
Total RNA of endometrial tissues was isolated from 20 μm-thick sections of frozen tissue using 
TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) followed the protocol described previously [57]. All 
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the RNA samples were treated with DNase (RNase-Free DNase Set, cat No. 79254, Qiagen, Valencia, 
CA, USA) before reverse transcription. The purity of RNA has been determined by OD260/280 ratio. 
The quality of RNA and cDNA was ensured by the results of pilot PCR in which clear specific DNA 
band of the target gene was observed in agarose gel electrophoresis. Poly-A RNA from human 
epididymis, skeletal muscle (s. muscle), testis, prostate, lung, placenta, trachea, kidney, peripheral blood 
lymphocyte (PBL), colon, liver, breast, and ovary were purchased from Clontech Laboratories (Clontech 
Laboratories, Inc., Mountain View, CA, USA). cDNA was synthesized from 1 μg of total RNA using the 
SuperScript™ kit (Invitrogen, Carlsbad, CA, USA). 20 μL of reverse transcription product was diluted 
to 100 μL and 2 μL used for each real-time PCR reaction. The cDNA sequences for human HE4 
transcript variants (HE4-V0 to -V4) and human 36B4 (internal control) and GAPDH (internal control) 
were obtained from the PubMed gene bank and primers were designed by using primer 3  
software [58]. All the primers were synthesized from IDT (Integrated DNA Technology). 36B4 is a 
ribosomal RNA and ubiquitously expressed in all the cells. Owing to its housekeeping function, and 
the fact that CT value of 36B4 is lower than the CT value of GAPDH, and 36B4 has lower variance, 
36B4 was used as a control experiment for real-time PCR. We have also used 36B4 as housekeeping 
gene in previously works [59–61]. Negative control has been performed on the same 96-well PCR 
plate to test the PCR specificity. Real-time PCR was performed following previously described 
protocols [57,61] in a 25 μL reaction containing 2 μL of cDNA, 12.5 μL of SYBR® Green PCR Master 
Mix (Stratagene, Cedar Creek, TX, USA) and 50 nM of forward and reverse primers, respectively. The 
ABI 7900HT Fast Real-time PCR® System (Applied Biosystems, Foster City, CA, USA) was used with 
the following regimen of thermal cycling: Stage 1: 1 cycle, 2 min at 50 °C; Stage 2: 1 cycle, 5 min at  
95 °C; Stage 3: 40 cycles, 15 s at 95 °C, 1 min at 60 °C.  
Relative mRNA concentrations were calculated as the following: The threshold cycle number (CT) 
at which PCR products reached a preset threshold value, which was defined as the value where all 
products were undergoing exponential amplification, was determined by the florescence detector. 
Real-time PCR for the housekeeping gene 36B4 was performed in the same plates as for HE4 
experiments. The HE4 real-time PCR results were standardized by those of 36B4 using the formula 
∆CT = CTHE4 − CT36B4 (CTHE4 and CT36B4, threshold values for HE4 and 36B4, respectively). Relative 
HE4 mRNA levels were expressed as fold over 36B4 mRNA levels (F = 2∆CT). The experiments were 
repeated at least twice and the CT for each sample was determined in duplicate or triplicate. For 
practical reasons, relatively HE4 mRNA levels were arbitrarily amplified by a factor of 100 or 10,000 
as indicated in figure legends. All the real-time PCR data were normalized with housekeeping gene. 
4.6. Statistical Analysis 
Mean values among different groups were compared (grade 1 or grade 3 endometrioid EC or 
papillary serous EC versus normal endometrium) using a post-hoc Bonferroni t test with the 
assumption that HE4 mRNA levels exhibited bimodal distribution and that the variances of the two 
samples were equal. Pearson’s correlation coefficient test was used to examine the relationship 
between the expression patterns of the five HE4 variants among normal tissues as well as normal  
and malignant endometrium. Pearson’s correlation coefficient test was also applied to study the 
relationship between HE4 mRNA levels and patient characteristics including age, surgical stage, and 
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disease free survival. To avoid overly influential observations, our data were log-transformed before 
statistical analysis. Correlations with a p value smaller than 0.05 and a coefficient close to 1.0 were 
considered statistically significant.  
5. Conclusions 
This study is to our knowledge the first one to demonstrate a tissue-specific distribution of HE4 
variants and establish an HE4 variant-specific correlation with survival in EC. Furthermore, we 
suggest that a variant-specific approach may prove useful for improving the current use of HE4 assays 
in the diagnosis, triage and postsurgical surveillance for the patient with EC.  
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